{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=8",
    "query": {
      "condition": "Her 2 Positive Breast Cancer",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 243,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T22:21:20.943Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05080842",
      "title": "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AC682",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Accutar Biotechnology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-11-12",
      "completion_date": "2024-04-04",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05080842"
    },
    {
      "nct_id": "NCT01434303",
      "title": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2/Neu Positive",
        "Invasive Breast Carcinoma",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lapatinib Ditosylate",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2012-01-10",
      "completion_date": "2016-02-16",
      "has_results": false,
      "last_update_posted_date": "2019-05-20",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434303"
    },
    {
      "nct_id": "NCT06105632",
      "title": "A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07220060 CDK4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 333,
      "start_date": "2024-01-09",
      "completion_date": "2028-01-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Los Angeles, California • Newport Beach, California + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06105632"
    },
    {
      "nct_id": "NCT02780401",
      "title": "Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2/Neu Negative",
        "No Evidence of Disease",
        "One or More Positive Axillary Nodes",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage III Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2016-09-02",
      "completion_date": "2022-10-08",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington • Madison, Wisconsin",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780401"
    },
    {
      "nct_id": "NCT00791037",
      "title": "Vaccine Therapy in Treating Patients With Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HER-2/neu peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "ex vivo-expanded HER2-specific T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2008-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-25",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791037"
    },
    {
      "nct_id": "NCT03685331",
      "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Advanced Breast Cancer",
        "BRCA2 Mutation",
        "BRCA1 Mutation"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2020-10-15",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685331"
    },
    {
      "nct_id": "NCT05304962",
      "title": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "RGT-419B",
          "type": "DRUG"
        },
        {
          "name": "RGT-419B in combination with hormonal therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regor Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-03-04",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05304962"
    },
    {
      "nct_id": "NCT05232916",
      "title": "Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLSI-100",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Greenwich LifeSciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 2250,
      "start_date": "2022-12-16",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05232916"
    },
    {
      "nct_id": "NCT07137416",
      "title": "Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Locally Advanced Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Metastatic HER2-Low Breast Carcinoma",
        "Metastatic HER2-Positive Breast Carcinoma",
        "Metastatic Hormone Receptor-Positive Breast Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Breast Carcinoma",
        "Unresectable HER2-Low Breast Carcinoma",
        "Unresectable HER2-Positive Breast Carcinoma",
        "Unresectable Hormone Receptor-Positive Breast Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pidnarulex",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Imaging Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-10-05",
      "completion_date": "2028-01-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07137416"
    },
    {
      "nct_id": "NCT04072952",
      "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Vepdegestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arvinas Estrogen Receptor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2019-09-22",
      "completion_date": "2026-03-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-14T22:21:20.943Z",
      "location_count": 16,
      "location_summary": "Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04072952"
    }
  ]
}